Welcome to our dedicated page for Supernus Pharma SEC filings (Ticker: SUPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Supernus Pharmaceuticals filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company focused on central nervous system diseases. Recent Form 8-K reports cover operating results, conference-call related earnings releases, material definitive agreements, executive compensation arrangements, and other material events tied to the company's CNS product portfolio and corporate obligations.
Proxy materials describe annual meeting voting matters, director elections, advisory executive compensation votes, auditor ratification, and equity incentive plan amendments. The filings also identify the company's common stock structure, exchange listing, shareholder voting mechanics, governance practices, and capital-structure disclosures.
SUPERNUS PHARMACEUTICALS, INC. Senior Vice-President & CFO Timothy C. Dec exercised performance share units and settled related taxes in stock. On March 6, 2026, he converted awards into 6,000 shares of common stock, with 2,883 shares withheld at $54.73 per share for tax obligations, leaving 8,232 shares held directly.
Supernus Pharmaceuticals SVP, Commercial Operations William Todd Horich reported a series of stock transactions involving performance-based awards and subsequent sales. On March 6, 2026, he exercised performance share units to acquire 7,500 shares of common stock at $0.00 per share. In connection with this vesting, the company withheld 3,455 shares at about $54.73 per share to cover tax obligations, as disclosed in the footnotes.
He then executed open-market sales of common stock, selling 4,438 shares at $54.00 on March 9 and 4,439 shares at $55.00 on March 10. After these transactions, his directly held common stock position reported in this filing was reduced to zero shares. The filing shows no remaining derivative holdings, indicating all reported performance share units tied to these transactions were fully settled.
Supernus Pharmaceuticals SVP William Todd Horich filed an initial ownership report showing his equity holdings in the company. The filing lists multiple employee stock options on common stock with exercise prices such as $39.4000 and $27.9400, expiring between 2028 and 2036, as well as restricted stock units and performance share units that vest in four equal annual installments beginning on dates including February 23, 2024, February 22, 2025, February 19, 2026 and February 18, 2027. He also holds 4,832 shares of common stock directly.
SUPN filed a Form 144 reporting a proposed sale of 4,438 common shares.
The notice lists restricted stock vesting under a registered plan on 02/19/2026 (544 shares), 02/22/2026 (1,003 shares) and 02/23/2026 (2,891 shares). The broker/agent listed is Morgan Stanley Smith Barney LLC.
Morgan Stanley Smith Barney LLC filed a Form 144 reporting proposed sales of 1,623 shares of Common stock related to restricted stock vesting under a registered plan. The filing lists vesting dates of 01/12/2023, 02/22/2023, and 02/22/2024 with share counts 747, 461, and 415, respectively.
Supernus Pharmaceuticals director Georges Gemayel reported an option exercise and related stock sales. On March 6, 2026, he exercised a director stock option for 7,905 shares, receiving common stock at an exercise price of $0.00 per share, and held 36,064 shares afterward.
He then sold 10,000 shares of common stock on March 5, 2026 at a weighted average price of about $53.71, and a further 8,787 shares on March 6, 2026 at about $53.00, in open-market transactions. After these sales, he directly owned 27,277 shares of Supernus common stock.
Georges Gemayel filed a Form 144 reporting planned and recent sales of common stock. The filing lists a sale on 03/05/2026 of 10,000 shares for $537,117.00. It also shows securities to be sold from exercises: 3,787 shares by exercise on 03/06/2026 and 5,000 shares previously exercised on 03/04/2026.
The notice references an exercise under a registered plan and cash transactions; timing and cash‑flow recipients are described in the entries tied to those exercise dates.
Supernus Pharmaceuticals President and CEO Jack A. Khattar reported the acquisition of 38,640 Performance Share Units at a price of $0.00 per unit. These units were awarded on February 22, 2024, with a portion vesting upon achievement of individual performance objectives set on June 24, 2024.
SUPERNUS PHARMACEUTICALS, INC. reported that Senior Vice-President & CFO Timothy C. Dec acquired performance share units. On the reported transaction date, 3,000 performance share units were credited to his direct holdings at no exercise price. According to a footnote, these units were originally awarded on February 22, 2024, with a portion vesting upon achievement of individual performance objectives established on June 24, 2024.